Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Xeris Biopharma Raises FY24 Total Revenue Outlook To $175M-$200M Vs. 184.43M Estimate (Prior View: $170M-$200M)

Author: Benzinga Newsdesk | May 09, 2024 07:09am

Posted In: XERS